GET DAILY SIGNALSTriSalus Life Sciences (TLSI): Analyst Targets Point to Significant Upside Potential
Key Takeaways
- The central $10 stock price target is the arithmetic mean of five verified analyst price targets (rounded from $10.40).
- The current price of about $2.80 implies roughly 255% upside to the $10 target—a very large move.
- The five analyst targets span a wide range, from a low of $7 to a high of $14, with a "Strong Buy" tilt overall.
- Key supports include growing revenue, reaffirmed full-year guidance, and a clinical pipeline beyond the core TriNav device.
- The biggest risks are persistent net losses, a sharp recent share decline, and heavy dependence on clinical and commercial execution.
- For more detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- You can also browse Trending AI Robots to see AI-driven trading ideas across the market.
Analyst Price Targets and Consensus View
Five current, attributable analyst price targets were reviewed for this analysis. H.C. Wainwright raised its target to $12 (October 2026), Lake Street holds an $8 target, Canaccord Genuity carries a $7 target, Maxim Group raised its target to $14 (from $10), and JonesTrading holds an $11 target. That produces a low-to-high range of $7 to $14 and a calculated mean of $10.40, which rounds to the $10 central target used throughout this article.
The spread is unusually wide—more than double from the lowest to the highest target—reflecting genuine disagreement about how quickly TriSalus Life Sciences, Inc. (TLSI) can scale revenue and move toward profitability. Every reviewed analyst rates the shares a Buy, so the debate is not about direction but about magnitude and timing. Bulls emphasize the PEDD platform's differentiation and the optionality of nelitolimod; the more cautious targets reflect tempered near-term growth and discount-rate assumptions after several downward revisions earlier in 2026. This $10 figure is a calculated mean, not an independently published consensus, and it is not a guarantee of future performance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of early November 2026, TLSI shares traded near $2.80, down sharply from roughly $3.90 a week earlier and well below the 52-week high of $7.95. Reaching $10 would require a rise of approximately 255%, a very large move for any stock, let alone a micro-cap with a market capitalization near $200 million.
Fundamentals show a company in transition. Trailing-twelve-month revenue was about $45 million (up roughly 25% year over year), but net income remained deeply negative at roughly -$57 million, with diluted EPS (earnings per share) around -$1.22. The path toward the target would require sustained double-digit revenue growth, meaningful operating-leverage improvements, and positive clinical readouts—none of which is yet locked in.
What Could Support a Move Toward the Target
Several factors could support the stock forecast. The company reaffirmed full-year 2026 revenue guidance of $54 million to $57 million, implying continued growth. The TriNav Infusion System has FDA clearance and serves a recurring interventional-radiology procedure market, providing a commercial base beyond clinical-stage risk. Nelitolimod, a Toll-like receptor 9 (TLR9) agonist being studied across multiple tumor types, offers additional upside if trial data are favorable. A high gross margin (around 87% in recent quarters) shows the device franchise is not structurally unprofitable at the product level, and the unanimous Buy ratings suggest analysts see valuation as depressed relative to potential.
What Could Prevent the Target From Being Reached
The obstacles are equally significant. TLSI is unprofitable, burning cash, and carries a negative P/E (price-to-earnings ratio) with substantial debt relative to equity. The stock's sharp mid-2026 decline and its drop around its November earnings date indicate fragile investor sentiment. As a micro-cap with limited liquidity, the shares are vulnerable to large percentage swings on modest news. If revenue growth slows, guidance is trimmed, clinical data disappoint, or the company needs dilutive financing, the $10 average analyst price target could look far more distant. Technical and psychological resistance also matters: the stock sits far below prior highs, and a multi-hundred-percent recovery is rare without a step-change in the business.
Technical Levels and Market Structure
From a technical standpoint, TLSI's 52-week range of $2.20 to $7.95 defines the relevant structure. The $2.20 area represents the durable support level tested earlier in 2026, while the $7.95 high is the primary resistance level overhead. The stock's recent slide toward the low end of that range suggests limited near-term momentum, and any move toward $10 would first require reclaiming intermediate levels in the $4-to-$5 zone before challenging the prior peak.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms vary in their assumptions. The most relevant near-term items are the company's quarterly earnings and any updates to the $54 million-to-$57 million revenue guidance, followed by data updates from the nelitolimod clinical programs and any FDA or regulatory developments. Investors should also watch analyst revisions—the wide $7-to-$14 range means a single target change can shift the average meaningfully—as well as broader small-cap and healthcare-sector sentiment and any capital-raising activity. From what I see, monitoring these elements closely helps clarify the path forward.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap such as TLSI, this type of automated monitoring can help traders identify changing trends and spot opportunities more efficiently than manual chart review. Traders can use the signals to watch positions, discover new setups, and track when momentum begins to turn. In my experience, these tools add a useful layer when evaluating names with wide analyst target ranges.
Final Assessment
The $10 central target—the average of five verified analyst price targets ranging from $7 to $14—implies a roughly 255% move from a recent price near $2.80. That is a very large climb, and while the unanimous Buy ratings, growing revenue, reaffirmed guidance, and pipeline optionality provide genuine support, the company's ongoing losses, fragile micro-cap trading, and the risk of clinical or financing setbacks are substantial counterweights. The target is best understood as an expression of analyst optimism over a roughly 12-month horizon rather than a forecast with certainty. Whether TLSI reaches $10 will depend most on sustained revenue execution and clinical progress, and investors should monitor earnings, guidance, and analyst revisions closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TLSI's Indicator enters downward trend
The Aroon Indicator for TLSI entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator formed such a pattern. In 139 of the 165 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLSI as a result. In 55 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for TLSI turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In 33 of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
The 50-day moving average for TLSI moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLSI's RSI Indicator exited the oversold zone, 21 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +8.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLSI advanced for three days, in 136 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
TLSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TLSI's P/B Ratio (30.552) is slightly higher than the industry average of (4.142). P/E Ratio (-2.444) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.459) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. TLSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement